Pulmonary Vascular Disease and Right Ventricular Dysfunction: Current Concepts and Future Therapies

Pulmonary arterial hypertension (PAH) is characterized by progressive obliteration of pulmonary arterioles leading to increased pulmonary vascular resistance, right heart failure, and death in 40-60% of PAH patients 5 years after diagnosis. Proliferation, migration, and resistance to apoptosis of vascular cells, as well as proliferative-inflammatory responses mediated by blood and fat cells contribute to disease development. Despite more than 15 published randomized clinical trials (RCT) that demonstrated moderate effectiveness in improving exercise capacity, the approved PH drugs have not led to a cure or substantial increase in survival for PAH. Hence, basic science and translational research focusing on the discovery of novel pathways in pulmonary vascular disease and right ventricular dysfunction, new drug targets, development of novel therapeutic paradigms, cell-based and pharmacotherapies, and their translation into RCTs, is urgently needed. This Keystone Symposia meeting will gather basic and clinical researchers working in the field of pulmonary vascular disease and right ventricular dysfunction. The focus is on basic science with strong impact on 1) our understanding of this fatal disease, and 2) discoveries with great potential to be translated into clinical practice in the near future. Late-breaking clinical studies on novel PAH therapies will also be presented.
+ show speakers and program
MONDAY, SEPTEMBER 10

16:00—20:00
Arrival and Registration

De Anza Foyer

TUESDAY, SEPTEMBER 11

07:30—08:30
Breakfast

De Anza 1-2
08:30—09:30
Welcome and Keynote Address
Registered attendees can view abstracts starting on 08/10/2012

De Anza 3
Stefanie Dimmeler, University of Frankfurt
The Role of Stem Cells in Angiogenesis and Vascular Repair

09:30—12:45
The Role of Stem Cells, Progenitor and Differentiated Blood Cells in Pulmonary Vascular Disease and Repair
Registered attendees can view abstracts starting on 08/10/2012

De Anza 3
* Duncan J. Stewart, Ottawa Hospital Research Institute, Canada

Stella Kourembanas, Children's Hospital Boston, Harvard Medical School, USA
Role of Bone Marrow Stromal Cells in the Repair of Chronic Lung and Pulmonary Vascular Disease

Margaret R. MacLean, University of Glasgow, UK
Serotonin and Estrogen in the Development of Pulmonary Arterial Hypertension

Paul M. Hassoun, Johns Hopkins University, USA
Cross-Talk between Macrophages, Granulocytes and Vascular Cells in Pulmonary Vascular Diseases

Mark L. Ormiston, University of Cambridge, UK
Short Talk: Impaired Natural Killer Cell Phenotype and Function in Pulmonary Arterial Hypertension and Animal Models of Disease

Izabela M. Chrobak, Boston University School of Medicine, USA
Short Talk: Endothelial GATA6 Deficiency Promotes Pulmonary Arterial Hypertension

Duncan J. Stewart, Ottawa Hospital Research Institute, Canada
Progenitor Cell Transplantation for Pulmonary Hypertension

10:50—11:10
Coffee Break

De Anza Foyer
12:45—13:15
Poster Setup

De Anza 1-2
12:45—14:30
On Own for Lunch and Recreation

13:15—22:00
Poster Viewing

De Anza 1-2
14:30—16:30
Workshop 1: How to Translate Basic Research Findings into Improvement of Patient Care - The Role of Industry

De Anza 3
Lynn Raju Punnoose, New York Presbyterian Weill Cornell, USA
Lessons from Computerized Models on Right Ventricular Assist Devices in Pulmonary Arterial Hypertension

Evelyn M. Horn, Weill Cornell, USA
New Devices for PH-Noninvasive Monitoring of Cardiac Output and RV Assist Devices

Matthew Thomas, Novartis Institutes for BioMedical Research, UK
Anti-Remodeling Therapies for Pulmonary Arterial Hypertension: Challenges for Drug Discovery

H. Ardeschir Ghofrani, Justus Liebig University Giessen, Germany
Preliminary/Unpublished Results - Randomized Controlled Trial

* Stuart Rich, University of Chicago Medical Center, USA
Panelist

Timothy M. Moore, NHLBI, National Institutes of Health, USA
Panelist

16:30—17:00
Coffee Available

De Anza Foyer
17:00—19:00
Growth Factors, TGF-beta/BMP Signaling and Pulmonary Vascular Disease
Registered attendees can view abstracts starting on 08/10/2012

De Anza 3
* Georg Hansmann, Hannover Medical School, Germany

* Paul M. Hassoun, Johns Hopkins University, USA

Marc Humbert, Hôpital Antoine-Béclère, AP-HP
New Insights into the Role of Cytokines, Chemokines and Growth Factors in Pulmonary Arterial Hypertension

Kenneth D. Bloch, Massachusetts General Hospital, USA
Role of BMPR-2 and BMP Signaling in PAH - Lessons from Murine Models

Mark P. de Caestecker, Vanderbilt University, USA
Short Talk: Chemical Chaperones Correct BMP Receptor Processing Errors in Hereditary Pulmonary Arterial Hypertension (HPAH)

Patricia A. Thistlethwaite, University of California, San Diego, USA
Notch Signaling in Pulmonary Vascular Disease

19:00—20:00
Social Hour w/ Lite Bites

De Anza 1-2
19:30—22:00
Poster Session 1

De Anza 1-2

WEDNESDAY, SEPTEMBER 12

07:30—08:30
Breakfast

De Anza 1-2
08:30—11:45
Metabolic Regulators in Pulmonary Vascular Disease
Registered attendees can view abstracts starting on 08/10/2012

De Anza 3
* Stephen L. Archer, University of Chicago Medical Center, USA

Peter F. Carmeliet, University of Leuven, Belgium
Vascular Metabolomics

Georg Hansmann, Hannover Medical School, Germany
The Protective Role of PPARgamma in Pulmonary Vascular Disease

Evangelos D. Michelakis, University of Alberta, Canada
Mitochondrial Modulators in Pulmonary Arterial Hypertension

Yong-Hu Fang, University of Chicago, USA
Short Talk: Inhibition of Glutaminolysis by 6-Diazo-5-Oxo-l-Norleucine (DON) Improves Right Ventricular Function in Monocrotaline Induced Pulmonary Hypertension

Kirsty M. Mair, University of Glasgow, UK
Short Talk: Beneficial Effects of an Aromatase Inhibitor in Established Hypoxia-Induced Pulmonary Arterial Hypertension

Nicholas Morrell, University of Cambridge, UK
Generation of Patient-Derived Induced Pluripotent Stem Cells to Study BMP Receptor Dysfunction

09:50—10:10
Coffee Break

De Anza Foyer
11:45—13:00
Poster Setup

De Anza 1-2
11:45—14:30
On Own for Lunch and Recreation

13:00—22:00
Poster Viewing

De Anza 1-2
14:30—16:30
Workshop 2: MicroRNAs and iPS Cells - Novel Tools and Targets in Cardiovascular Biology and Pulmonary Vascular Research

De Anza 3
* Nicholas Morrell, University of Cambridge, UK

Jenny Grieve, University of Glasgow, Scotland
The Role of miR-451 in the Development of Pulmonary Arterial Hypertension (PAH)

Kylie M. Drake, Cleveland Clinic, USA
Treatment with Chloroquine Rescues Smad-Mediated microRNA Processing in Heritable Pulmonary Arterial Hypertension

Guillaume Margaillan, Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec (CRIUCPQ), Canada
miR-204 Accounts for HIF-1alpha Activation in Both Human and Experimental Pulmonary Arterial Hypertension

Allison R. Prewitt, Vanderbilt University, USA
Caveolar Defects in Hereditary Pulmonary Arterial Hypertension (HPAH)

Edda Spiekerkoetter, Stanford University, USA
FK506 - Identified in a High-Throughput Screen to Increase BMPR2 Signaling - Reverses Pulmonary Hypertension by Rescuing Endothelial Dysfunction

Roxane Paulin, University of Alberta, Canada
A MicroRNA Signature Characterizing the Transition from a Compensated to a Decompensated Right Ventricle

16:30—17:00
Coffee Available

De Anza Foyer
17:00—19:00
The Right Ventricle in Pulmonary Hypertension: Cardiomyocyte Function and Hemodynamic Performance
Registered attendees can view abstracts starting on 08/10/2012

De Anza 3
* Evangelos D. Michelakis, University of Alberta, Canada

* Kurt R. Stenmark, University of Colorado Denver, USA

Stephen L. Archer, University of Chicago Medical Center, USA
Right Ventricular Function and Metabolism in Pulmonary Hypertension: Mechanisms and Potential Metabolic Therapies

Titus Kühne, German Heart Institute, Germany
Assessment of Right Ventricular Function by MRI and Pressure-Volume Loops

Andrew Redington, Hospital for Sick Children, Canada
Interactions between Right and Left Ventricle in Pulmonary Hypertension

Simon C. Rowan, University College Dublin, Republic of Ireland
Short Talk: Haploinsufficiency of Gremlin Augments NOS Expression and Activity in the Hypoxic Pulmonary Circulation

19:00—20:00
Social Hour w/ Lite Bites

De Anza 1-2
19:30—22:00
Poster Session 2

De Anza 1-2

THURSDAY, SEPTEMBER 13

07:30—08:30
Breakfast

De Anza 1-2
08:30—11:30
MicroRNAs in Proliferative Vascular Disease
Registered attendees can view abstracts starting on 08/10/2012

De Anza 3
* Margaret R. MacLean, University of Glasgow, UK

Andrew H. Baker, University of Glasgow, UK
MicroRNAs in Vascular Remodeling and PAH

Norbert F. Voelkel, Virginia Commonwealth University, USA
Histone Deactylation in the Right Ventricle and Pulmonary Vasculature

Joseph Loscalzo, Brigham and Women's Hospital, Harvard Medical School, USA
Hypoxamirs in the Pulmonary Endothelium

Sebastien Bonnet, Université Laval, Canada
Role for DNA Repair and miRNAs in the Epigenetics Abnormalities Seen in PAH

Pawel Stankiewicz, Baylor College of Medicine, USA
Short Talk: Deletions of lncRNAs Cause a Lethal Lung Developmental Disorder Showing Parent of Origin Effects

09:50—10:10
Coffee Break

De Anza Foyer
11:30—14:30
On Own for Lunch and Recreation

14:30—15:00
Coffee Available

De Anza Foyer
15:00—17:00
Innovative Clinical PAH Trials

De Anza 3
Stuart Rich, University of Chicago Medical Center, USA
Clinical Trial Design Issues in Pulmonary Hypertension

Evangelos D. Michelakis, University of Alberta, Canada
and

Martin R. Wilkins, Imperial College London, UK
Dichloroacetate (DCA) for the Treatment of Pulmonary Hypertension

Mark R. Nicolls, Stanford University School of Medicine, USA
Targeting Immunity in the Treatment of PAH: The Rituximab SSc-PAH Trial

* Marc Humbert, Hôpital Antoine-Béclère, AP-HP
Panelist

Duncan J. Stewart, Ottawa Hospital Research Institute, Canada
Panelist

17:00—18:00
Social Hour w/ Lite Bites

De Anza 1-2
18:00—
On Own for Dinner


FRIDAY, SEPTEMBER 14

07:30—08:30
Breakfast

De Anza 1-2
08:30—11:45
Pulmonary Hypertension in Parenchymal Lung and Thromboembolic Diseases
Registered attendees can view abstracts starting on 08/10/2012

De Anza 3
* Stella Kourembanas, Children's Hospital Boston, Harvard Medical School, USA

* Mark A. Krasnow, Stanford University School of Medicine, USA
Building the Pulmonary Artery

Bernard Thébaud, University of Alberta, Canada
Progenitor Cells in Diaphragmatic Hernia, Pulmonary Hypoplasia and PH Associated with Neonatal Lung Injury

Jane A. Mitchell, Imperial College London, UK
The Role of PPAR beta/delta in Pulmonary Hypertension

Lei Zhou, Texas Heart Institute, USA
Short Talk: ELPC-Based Prostacyclin Gene Therapy Rescues Monocrotaline-Induced Pulmonary Arterial Hypertension

Stuart W. Jamieson, University of California, San Diego Medical Center, USA
Pulmonary Hypertension as a Result of Chronic Pulmonary Embolism-Surgical Treatment

Aiko Ogawa, National Hospital Organization Okayama Medical Center, Japan
Short Talk: Thrombin Induces Proliferation of Cells from Patients with Chronic Thromboembolic Pulmonary Hypertension via Akt/mTOR Pathway

09:50—10:10
Coffee Break

De Anza Foyer
11:45—14:30
On Own for Lunch and Recreation

14:30—16:30
Workshop 3: Vascular Metabolomics and Proteomics: Where Are the Novel Biomarkers for Pulmonary Vascular Diseases?

De Anza 3
* Martin R. Wilkins, Imperial College London, UK

Steeve Provencher, Institut Universitaire de Cardiologie et de Pneumologie de Quebec, Canada
Pim-1: A New Biomarker for Diagnosis and Severity Assessment of Pulmonary Arterial Hypertension

Alex M.K. Rothman, University of Sheffield, UK
Whole Blood miRNA Expression in Pulmonary Arterial Hypertension (PAH) Reveals Down-Regulation of MicroRNA-140-5p in Idiopathic and Scleroderma-Associated PAH

Jessie R. Lavoie, Ottawa Hospital Research Institute, Canada
Proteomic Analysis Identifies Translationally Controlled Tumor Protein (TCTP) as a Potential Novel Mediator of Occlusive Vascular Remodeling in Pulmonary Arterial Hypertension

Ferhaan Ahmad, University of Pittsburgh, USA
Pulmonary Arterial Hypertension Induces Gene Expression Changes in the Right Ventricle in Advance of Right Ventricular Failure that Are More Severe in Female Rats

Giovanna Frazziano, Ri.MED Foundation/ISMETT, Italy
Nox-Derived ROS Is Increased in a Model of Pressure Overload in Mouse Right Ventricle

Elena A. Goncharova, University of Pennsylvania, USA
mTORC2 Coordinates Energy Metabolism, Proliferation and Survival of Vascular Smooth Muscle Cells in Idiopathic PAH

Kathryn N. Farrow, Northwestern University, USA
Disruption of cGMP Signaling in Small Pulmonary Arteries Occurs Rapidly and Persists in BPD Mice with Pulmonary Hypertension

16:30—17:00
Coffee Available

De Anza Foyer
17:00—19:00
Pulmonary Arterial Hypertension - Current Concepts and Future Therapies

De Anza 3
* Stephen L. Archer, University of Chicago Medical Center, USA

* Georg Hansmann, Hannover Medical School, Germany

* Margaret R. MacLean, University of Glasgow, UK

Kurt R. Stenmark, University of Colorado Denver, USA
Chronic Inflammation, Autoimmunity and Epigenetics: A Critical Drug-Targetable Triumvirate in Pulmonary Hypertension

Jeffrey R. Fineman, University of California, San Francisco, USA
Early Endothelial Dysfunction: Lessons Learned from a Model of Congenital Heart Disease with Increased Pulmonary Blood Flow

Martin R. Wilkins, Imperial College London, UK
Novel Biomarkers for Pulmonary Vascular Disease and Right Ventricular Dysfunction

Timothy M. Moore, NHLBI, National Institutes of Health, USA
Panelist

19:00—20:00
Social Hour w/ Lite Bites

De Anza 1-2
20:00—23:00
Entertainment

De Anza 1-2

SATURDAY, SEPTEMBER 15


Departure


*Session Chair †Speaker invited, not yet responded.

10 Sep - 15 Sep 2012
Monterey
United States of America
meeting website